Distalmotion has raised $150 million in new financing. The company says this “significant fundraise reinforces the confidence” of its existing investors led by Revival Healthcare Capital. Dexter, Distalmotion’s robotic platform, is in day-to-day clinical use in Europe, successfully treating patients across a multitude of complex and high-volume procedures in general surgery, gynecology, urology.
Distalmotion has raised $90 million in Series E financing to support the global commercialization of its surgical robot Dexter. Revival Healthcare Capital led the round with participation from 415 Capital, as well as existing investors. CE-marked Dexter shifts the paradigm of robotic surgery by bringing the surgeon back into the sterile field, allowing direct patient…